Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Conditions

• Diabetes
• Diabetes Mellitus, Type 2

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• semaglutide — DRUG
  Oral administration once daily.
• placebo — DRUG
  Oral administration once daily.

Study Details

This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.

Key Dates

Start date

Sep 20, 2016

Status verified

Feb 2020

Primary completion

Apr 10, 2018

Completion

May 15, 2018

Study Design

Enrollment

324 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Semaglutide
• Placebo Comparator: Placebo

Primary Outcome Measure

Change in HbA1c [ Time Frame: Week 0, week 26 ]

Locations (60)

Find similar trials in Tuscumbia, AL

Related Studies

• Diabetes and Heart Disease Risk in Blacks
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Urinary Vitamin C Loss in Diabetic Subjects
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Personalized Environment and Genes Study
  Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
• Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations
  Enrolling By Invitation · National Human Genome Research Institute (NHGRI) · Bethesda, Maryland